NCT02793466View on ClinicalTrials.gov

Durvalumab in Pediatric and Adolescent Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

November 30, 2022

Study Completion Date

April 30, 2023

Conditions
Solid TumorLymphomaCentral Nervous System Tumors
Interventions
DRUG

Durvalumab; MEDI4736

IV Infusion every 2 weeks for a maximum of 26

Trial Locations (1)

90027

Children's Hospital Los Angeles, Los Angeles

All Listed Sponsors
lead

Leo Mascarenhas

OTHER

NCT02793466 - Durvalumab in Pediatric and Adolescent Patients | Biotech Hunter | Biotech Hunter